Are Regulatory Age Limits in Pediatric Melanoma Justified?

Rose, Klaus; Walson, Philip D

Rose, Klaus; Walson, Philip D.

Afiliación

Rose K; klausrose Consulting, Riehen, Switzerland.
Walson PD; Department of Clinical Pharmacology, University Medical Center, Goettingen, Germany.

Curr Ther Res Clin Exp ; 90: 113-118, 2019.

Article en En | MEDLINE | ID: mdl-31388365

Palabras clave

better medicines for children; critical view of pediatric investigation plans; pediatric drug development; pediatric legislation; pediatric study plan

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677782
https://dx.doi.org/10.1016/j.curtheres.2019.01.003

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Curr Ther Res Clin Exp Año: 2019 Tipo del documento: Article País de afiliación: Suiza

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677782
https://dx.doi.org/10.1016/j.curtheres.2019.01.003

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Curr Ther Res Clin Exp Año: 2019 Tipo del documento: Article País de afiliación: Suiza